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Abstract
Background: Gastrin Releasing Peptide receptor (GRPr)-based radioligands have
shown great promise for diagnostic imaging of GRPr-positive cancers, such as
prostate and breast.
The present study aims at developing and evaluating a versatile GRPr-based probe
for both PET/SPECT imaging as well as intraoperative and therapeutic applications.
The influence of the versatile chelator AAZTA5 on the radiometal labelling properties
and the in vitro performance of the generated radiotracers were thoroughly
investigated.
The GRPr-based antagonist D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 was functionalized
with the chelator 6-[Bis (carboxymethyl)amino]-1,4-bis (carboyxmethyl)-6-methyl-1,4-
diazepane (AAZTA5) through the spacer 4-amino-1-carboxymethyl-piperidine (Pip) to obtain
AAZTA5-Pip-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 (LF1). LF1 was radiolabelled with
gallium-68 (PET), indium-111 (SPECT, intraoperative applications) and lutetium-177 (therapy,
SPECT). In vitro evaluation included stability studies, determination of lipophilicity, protein-
binding studies, determination of Kd and Bmax as well as internalization studies using the
epithelial human prostate cancer cell line PC3. In vitro monotherapy as well as
combination therapy studies were further performed to assess its applicability as
a theranostic compound.
(Continued on next page)
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Results: LF1 was labelled with gallium-68, indium-111 and lutetium-177 within 5
min at room temperature (RT). The apparent molar activities (Am) were ranging
between 50 and 60 GBq/μmol for the 68Ga-labelled LF1, 10–20 GBq/μmol for the
111In- and 177Lu-labelled LF1. The radiotracers were stable for a period of 4 h
post labeling exhibiting a hydrophilic profile with an average of a LogDoctanol/PBS
of − 3, while the bound activity to the human serum protein was approximately
10%. 68/natGa-LF1, 177/natLu-LF1 and 111/natIn-LF1 exhibited high affinity for the
PC3 cells, with Kd values of 16.3 ± 2.4 nM, 10.3 ± 2.73 nM and 5.2 ± 1.9 nM,
respectively, and the required concentration of the radiotracers to saturate the
receptors (Bmax) was between 0.5 and 0.8 nM which corresponds to
approximately 4 × 105 receptors per cell. Low specific internalization rate was
found in cell culture, while the total specific cell surface bound uptake always
exceeded the internalized activity. In vitro therapy studies showed that inhibition
of PC3 cells growth is somewhat more efficient when combination of 177Lu-
labelled LF1 with rapamycin is applied compared to 177Lu-laballed LF1 alone.
Conclusion: Encouraged by these promising in vitro data, preclinical evaluation
of the LF1 precursor are planned in tumour models in vivo.
Keywords: Gastrin releasing peptide receptor (GRPr), AAZTA, Prostate cancer,
Imaging, Peptide radionuclide therapy
Background
The need to diagnose, prevent, and treat cancer is greater than ever, since cancer-
associated deaths are still a major cause of deaths. Early detection is essential for effect-
ive treatment of the disease, hence, many efforts have been made to identify cancer re-
lated targets and to further investigate their implication in cancer management (Kumar
et al. 2006). The G protein-coupled receptors (GPCR) are of high importance since they
have been identified as valuable targets for the development of specific radiotracers for
solid tumor imaging in the field of nuclear medicine. The fundamental component for
the successful development of GPCR-based radioligands for in vivo tumor imaging is
the GPCR overexpression on tumors in combination with their low expression and lim-
ited density in the surrounding healthy organs (Reubi 2003), with somatostatin receptor
being the first to be defined for in vivo imaging (Gibril et al. 1996). The successful clin-
ical translation of somatostatin receptor targeting was the driving force for the identifi-
cation of additional GPCR with the potential to be used for peptide receptor targeted
diagnostic and therapeutic applications (Reubi 2013). Gastrin Releasing Peptide recep-
tor (GRPr) that is overexpressed on a variety on human tumors, represents another tar-
get with high interest in nuclear medicine (Yu et al. 2013).
A high number of GRPr-based radiotracers, both agonists and antagonists, mainly de-
rived from the N-terminal truncated octapeptide bombesin (7–14), have shown promis-
ing results (Mansi et al. 2016). GRPr-based radioagonists were the first to be developed.
Although extensive preclinical research has been reported, only few radiotracers have
been clinically assessed, mainly because of their mitogenic properties and the side
effects. The diagnostic accuracy of the 68Ga-labelled BZH3 was investigated in patients
with gastrointestinal stromal tumors and gliomas (Dimitrakopoulou-Strauss et al. 2007;
Strauss et al. 2012). Clinical trials have also been performed with the GRPr agonist
AMBA, labelled with gallium-68 and lutetium-177 in patients with various cancers, to
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assess its applicability as diagnostic as well as therapeutic radiopharmaceutical (Baum
et al. 2007; Bodei et al. 2007). Furthermore, the feasibility of RP527 labelled with
technetium-99 m was evaluated in patients with prostate and breast cancer (Van de
Wiele et al. 2001).
The significant finding of the somatostatin radioantagonists being preferable to radio-
agonists for in vivo peptide receptor targeting (Ginj et al. 2006) stimulated the shift to-
wards the development of GRPr antagonists too (Cescato et al. 2008). A plethora of
radioantagonists have been evaluated preclinically and since 2013 several clinical trials
have been performed using GRPr radioantagonists (RM2 (or BAY 86-7548), RM26,
NODAGA-MJ9, SB3, NeoBOMB1, TE2AAR06, BAY 86-4367) labelled with gallium-68,
fluorine-18, cupper-64, lutetium-177, with RM2 radiolabelled with gallium-68 being the
most deliberated one (Kähkönen et al. 2013; Roivainen et al. 2013; Wieser et al. 2014;
Sah et al. 2015; Maina et al. 2016; Nock et al. 2017; Gnesin et al. 2018; Minamimoto
et al. 2018; Zhang et al. 2018; Fassbender et al. 2019; Touijer et al. 2019). Baratto et al.
recently used RM2 radiolabelled with gallium-68 to map its physiological distribution
in humans. Pancreas was the organ with the highest uptake, followed by mild to mod-
erate uptake in the gastrointestinal tract while the radiotracer is eliminated through the
urinary tract (Baratto et al. 2020). The above radioantagonists were evaluated in pa-
tients with newly diagnosed prostate cancer (PC) and at biochemical recurrence of
prostate cancer (BCR PC). In summary, the studies outline that the radioantagonists
can be safely administrated to patients. They showed high detection rate of primary PC
and BCR PC, were able to detect more lesions compared to [18F] fluoroethylcholine
and [99mTc]Tc-MDP, apparent performance was improved when compared with the
radioagonist 68Ga-BBN and exhibited higher detection rates compared to MRI. RM2,
RM26 and SB3 labelled with gallium-68 have also been used in few pilot studies to
evaluate their detection rate in patients with primary breast cancer (Maina et al. 2016;
Stoykow et al. 2016; Zang et al. 2018). These studies suggest that GRPr expression is
correlated with estrogen receptors (ER) positive tumors, paving thus the way to expand
additional the use of GRPr antagonists as a therapeutic tool.
Peptide receptor radionuclide therapy (PRRT) consists an important treatment option
especially in the management of inoperable and metastatic tumors (Kwekkeboom et al.
2008). However, several approaches, such as changes of the radioligand, dosimetry and
combination therapy with different agents such as radiosensitisers, have been investi-
gated aiming at improving the response rate and survival. Radiosensitization is consid-
ered an outstanding addition in cancer treatment. Inhibition of the phosphoinositide 3-
kinase protein kinase/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway,
which could be activated by PRRT, causes radiosensitization (Gomez-Pinillos and Fer-
rari 2012). PI3K/Akt/mTOR regulates several physiological functions such as control of
cell metabolism, growth, proliferation and survival. Studies also report that PI3K/Akt/
mTOR is activated, in particular in 30%–50% of PC, mainly due to the amplification of
gene encoding components, advocating that targeted inhibition of those individual
components of the signaling cascade might be a solid strategy for cancer therapy
(Gomez-Pinillos and Ferrari 2012). Rapamycin which is a mTOR inhibitor, inhibits
tumor growth, angiogenesis, metastasis and causes apoptosis in cancer cell lines as well
as in tumor mouse models (Konings et al. 2009). The so far attempts to improve the
treatment effect of prostate cancer, when using GRPr-analogues, involve dosimetry
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studies. The first in human dosimetry study with 177Lu-labelled RM2 was recently pub-
lished. The therapy was well tolerated without side effects. Pancreas was the dose-
limiting organ, bone metastases had the highest uptake, followed by lymph nodes and
soft tissue lesions (Kurth et al. 2020). These encouraging data pave the way for more
intensive efforts, preclinicaly as well as in clinical settings, investigating several treat-
ment options of PC.
Herein, the antagonistic statine-based GRPr peptide H-D-Phe-Gln-Trp-Ala-Val-Gly-
His-Sta-Leu-NH2 was functionalized with the chelator 6-[Bis (carboxymethyl)amino]-1,
4-bis (carboyxmethyl)-6-methyl-1,4-diazepane (AAZTA5) via the positively charged
spacer 4-amino-1-carboxymethyl-piperidine (Pip) to obtain AAZTA5-Pip-D-Phe-Gln-
Trp-Ala-Val-Gly-His-Sta-Leu-NH2 (LF1) (Fig. 1). LF1 was radiolabelled with gallium-
68, indium-111 and lutetium-177. One of our goals was to investigate the influence of
the versatile bifunctional chelator AAZTA5 on the GRPr-based antagonist with regard
to its receptor binding affinity and the in vitro performance of the generated radio-
tracers. Furthermore, the assessment of its potential in serving as theranostic com-
pound for GRPr-positive tumors, in in vitro monotherapy as well as combination
therapy studies in the presence of rapamycin, is also reported. The potent GRPr based
antagonist RM2 was used as the reference compound (Fig. 1).
Materials and methods
Reagents and instrumentation
All reagents and solvents were of the best grade available and were obtained from
Sigma-Aldrich, Merck, Fluka, AlfaAesar, VWR, AcrosOrganics and Fisher Scientific
Fig. 1 Schematic structures of LF1 and RM2
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and used without further purification. They were provided with a septum. All culture
reagents were from Gibco BRL, Life Technologies (Grand Island, NY). [177Lu]Lu3+ and
[111In]In3+ were obtained from Isotope Technologies Garching GmbH (ITG) (Munich,
Germany) and b.e.Imaging GmbH (Baden-Baden, Germany), respectively. The Gallia-
Pharm® Ge-68/Ga-68 generator was available from Eckert & Ziegler (Berlin, Germany).
Deuterated solvents for Nuclear Magnetic Resonance (NMR) spectra were commercially
available by Deutero. Thin layer chromatography plates from Merck, silica gel 60 F254
coated aluminium plates, were used for the analysis. Silica gel 60 (core size 0.063 / 0.200
mm) from Macherey-Nagel was used for purification by column chromatography.
The purification of the peptide was performed by semipreparative Reverse-Phase
High Performance Liquid Chromatography (RP-HPLC) on a 120–5 C18 Nucleosil
column (250 × 21 mm) applying a linear gradient of 15–90% solvent B in 25 min at
a flow rate of 12 mL / min (solvent A, 0.1% trifluoroacetic acid (TFA) / water
(H2O); solvent B, 0.1%TFA / Acetonitrile (ACN).
The quality control of the peptides as well as the radiolabelled compounds was per-
formed by analytical RP-HPLC from Knauer advanced scientific instrument equipped
with a Knauer Smartline Manager 5000, a Smartline Pump 1000 and a Smartline UV De-
tector 2600. The RP-HPLC runs were performed on an analytical 120–5 C18 Nucleosil
column (250 × 4.5mm) applying a linear gradient of 15–90% solvent B in 25min at a flow
rate of 1 mL / min. (solvent A, 0.1% TFA / H2O; solvent B, 0.1% TFA / ACN). Ultraviolet
detection was performed using a Knauer detector at 240 nm. For radioactivity measure-
ment, a Na (TI) well-type scintillation Gina star was used. The radiotracer solutions were
prepared by dilution with 0.9% NaCl.
The human prostate adenocarcinoma cell line PC3 was obtained from CLS Cell Lines
Service GmbH, (Eppelheim, Germany). Cell culture media Dulbecco’s Modified Eagle
Medium (DMEM) with GlutaMax-I Supplement, F-12 Nutrient Mixture with GlutaMax-I
Supplement, Dubecco’s Phosphate Buffered Saline (DPBS), Fetal Bovine Serum (FBS),
Trypsin-EDTA and antibiotic solution Penicillin-Streptomycin were from Gibco BRL, Life
Technologies (Grand Island, NY) and purchased from ThermoFisher (Switzerland).
Electrospray Ionization - Mass Spectrometry (ESI-MS) mass spectra were acquired
on a Bruker Daltonics Esquire 3000 plus device.
The 1H-, 13C-NMR measurements were performed on a Bruker Avance III HD 400
(400MHz) or Avance III 600 (600MHz). LC / MS spectra were measured on an Agilent
Technologies 1220 Infinity LC system coupled to an Agilent Technologies 6130B Single
Quadrupole Liquidchromatography - Mass spectrometry (LC / MS) system.
Thin Layer Chromatography (TLC) scans were acquired on an Elysia Raytest TLC
scanner using the Gina Star TLC software.
Quantitative γ-counting was performed with a Cobra II Gamma Counter from Pack-
ard Instrument (USA).
All experiments were carried out twice in triplicates.
Synthesis of the prochelator AAZTA5-(tBu)4
The precursor AAZTA5-(tBu)4 was successfully synthesized over 4-steps following the
protocol described by Sinnes et al. (2019b). Briefly, the synthesis steps are described
below and shown in Fig. 2:
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1,4-Dibenzyl-6-methylpentanoate-6-nitroperhydro-1,4-diazepane (1)
2-nitrocyclohexanone (2.00 g; 13.9 mmol) and Amberlyst A21 (1.05 g) were mixed
with dry methanol (MeOH) (35 mL). The solution was heated to 60 °C and stirred
under reflux for 1 h. N,N′-dibenzylethylene-diamine (3.36 g; 13.9 mmol) and
paraformaldehyde (1.67 g; 55.5 mmol) were added to the solution. The suspension
was heated to 80 °C and stirred overnight. After completion of the reaction, the
suspension was filtered and the filtrate concentrated under vacuum. After column
chromatographic purification (Cyclohexane (CH) / Ethyl Acetate (EA); 9:1; Rf = 0.27)
a yellow oil was obtained as product 1 (5.20 g; 11.8 mmol; 85%).
1,4-Di (tert-butylacetate)-6-methylpentanoate-6-amino-di (tert-butylacetate)-perhydro-
1,4-diazepine (3)
1 (1.05 g, 2.39 mmol) was added to a solution containing Pd (OH)2 / C (0.62 g, 10
wt%) and abs. Ethanol (EtOH) (20 mL). Acetic acid (411 μL; 7.18 mmol) was added,
the solution was saturated with hydrogen and stirred overnight at room
temperature. After completion of the reaction, Pd (OH)2 / C was filtered over Celite
and the filtrate was concentrated under vacuum. Crude product 2, a white-yellowish
solid, was used for further reaction without further purification.
2 (1.05 g; 2.39 mmol) and K2CO3 (1.32 g; 9.57 mmol) were dissolved in dry ACN (30
mL). tert-butyl bromoacetate (1.41 mL; 9.57 mmol) and potassium iodide (0.80 g)
were added and stirred overnight at 40 °C. The solution was concentrated under
vacuum and purified by column chromatography (CH / EA, 7:1; Rf = 0.15).
Compound 3 was obtained as yellow oil (0.89 g; 1.30 mmol; 54%).
1,4-Di (tert-butylacetate)-6-pentanoicacid-6-(amino-di (tert-butylacetate))-perhydro-1,4-
diazepine (4)
3 (293 mg, 0.43 mmol) was dissolved in 1,4-dioxane / H2O (2:1; 6 mL). 1M LiOH
solution (641 μL; 0.64 mmol) was added and stirred overnight at RT. After
completion of the reaction, the solution was concentrated, the residue concentrated
with 1M NaHCO3 solution and extracted several times with chloroform. The
organic phase was extracted with H2O, dried with Mg2SO4 and concentrated under
vacuum. Compound 4 was obtained a yellowish oil (224 mg; 0.33 mmol; 76%).
Fig. 2 Synthetic scheme of AAZTA5-(tBu)4: a paraformaldehyde, MeOH, Amberlyst A21; b Pd (OH)2/C,
CH3COOH, EtOH, K2CO3; c tert-butylbromacetate, MeCN, K2CO3, KI; d 1 M LiOH, 1,4-dioxane/H2O (2:1)
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Synthesis of the chelator-peptide conjugate
The peptide-chelator conjugate was synthesized manually using standard fluorenyl-
methoxycarbonyl protecting group (Fmoc) chemistry and Rink amide 4-
methylbenzhydrylamine resin. The spacer (Pip) and the prochelator (AAZTA5-(tBu)4)
were consecutively coupled to the peptide using 1-[Bis (dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b] pyridinium 3-oxid hexafluorophosphate (HATU) as an activating
agent. The cleavage of the peptide and the simultaneous deprotection of the side chain-
protecting groups was performed using TFA / triisopropylsilane (TIPS) / H2O (95 / 2.5
/ 2.5). The crude conjugate was further purified by semipreparative RP-HPLC as de-
scribed in the “Reagents and Instrumentation” section.
Radiochemistry
68Ga-labelled LF1
The 68Ga-labelled radiotracer was prepared within 5 min, using the Modular-Lab
PharmTracer module by Eckert & Ziegler (Berlin, Germany). The radiolabeling per-
formance of LF1 was assessed at pH 4.0 (0.2 M sodium acetate buffer), at RT using a
conjugate amount of 5–20 μg (approximately 3–12 nmol). Briefly, the Ge-68/Ga-68
generator was eluted with 5 mL HCl 0.1 N and the eluate (~ 400MBq) was loaded onto
a cation exchange column (Strata-XC, Phenomenex). Gallium-68 was eluted with
700 μL of a mixture of 5.5M NaCl / 0.1M HCl directly in a vial containing 400 μL of
1.8M sodium acetate buffer, 2 mL H2O, 200 μL of EtOH, 5 mg ascorbic acid / 20 μL
H2O and the tested amount of the conjugate, followed by SepPak C-18 purification to
remove uncomplexed radiometal.
177Lu- and 111In-labelled LF1 and 177Lu-labelled RM2
The 177Lu- and 111In-labelled radiotracers were prepared by dissolving 5–10 μg (ap-
proximately 3–6 nmol) of LF1 in 250 μL ammonium acetate buffer (0.5 M, pH 5.4),
followed by incubation with [177Lu]Lu3+ (30–100MBq) or [111In]In3+ (approximately
35–40MBq) for 10 min at RT and were used without any further purification step.
After the labelling with gallium-68, lutetium-177 or indium-111 and the quality con-
trol of the generated radiotracers, one equivalent of either natGa (NO3)3 or
natLuCl3 x
6H2O or
natInCl3 x 2H2O were added to the relevant radiolabelling solutions. The final
solutions were incubated at RT for 10 min to obtain structurally characterized homoge-
neous ligands which were used for the saturation binding studies. The homogeneity
was determined by HPLC, showing one peak.
Quality control of the radiotracers / stability
Chemical and radiochemical purity of the tested solutions were determined using an
analytical Nucleosil 100–5 C18 column applying the conditions described in the “Re-
agents and Instrumentation” section.
The presence of free gallium-68 and 68Ga-labelled colloid in the 68Ga-labelled LF1
preparation was quantified by radio thin layer chromatography (Radio-TLC) using Sil-
ica gel 60-plates and two different mobile phase eluents: a) 0.1M Na-citrate; b) MeOH
/ 1M ammonium acetate (1 / 1, v / v). Using the first Radio-TLC eluent, the radiopep-
tide product and 68Ga-labelled colloid remain immobilized at the starting point,
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whereas free gallium-68 move with the mobile phase. When the second eluent is used,
only the labelled peptide moves with the mobile phase / solvent front.
The stability of the newly prepared radiotracers was tested via RP-HPLC for a period
of 4 h post labeling.
Lipophilicity
The lipophilicity (LogDoctanol/PBS, pH 7.4) was estimated by the “shake-flask” method:
The labelled conjugates (100 pmol; 1.1MBq, 1.2MBq and 0.5MBq for 68Ga-, 177Lu-
and 111In-labelled LF1 respectively) were added to a solution of 1-octanol (500 μL) and
of PBS (500 μL, pH 7.4). The mixture was vortexed for 1 h to reach the equilibrium and
then centrifuged (3000 rpm) for 10 min. From each phase, an aliquot (50 to 100 μL)
was pipetted out and measured in a gamma-counter. Each measurement was repeated
five times. Care was taken to avoid cross-contamination between the phases. The parti-
tion coefficient was calculated as the average log ratio of the radioactivity in the organic
fraction and the PBS fraction.
Protein binding studies in human plasma
68Ga-, 177Lu- and 111In-labelled LF1 (100 pmol; 1.1 MBq, 1.2 MBq and 0.5 MBq, re-
spectively) were incubated with human plasma (0.5 mL) at 37 °C for 30 min and 60 min
respectively. When the incubating period was completed, proteins were precipitated
with a solution of 1 mL of MeOH / ACN (1:1). Centrifugation (10 min, 9660 g) for the
separation of proteins was then performed. After careful separation of the two phases,
the respective activities were measured in a gamma-counter, followed by determination
of the percentage of each radiotracer which does not bind to the plasma proteins.
Cell culture
The human prostate epithelial adenocarcinoma cell line PC3, which is known to over-
express GRPr, was cultured at 37 °C and 5% CO2 in Dulbecco’s Modified Eagle Medium
(DMEM) with GlutaMAX-I supplement and F-12 Nutrient Mix with GlutaMAX-I sup-
plement in a ratio of 1:1. The medium was supplemented with 10% fetal bovine serum
(FBS), penicillin (100 U / mL) and streptomycin (100 μg / mL).
Saturation binding studies
For receptor saturation analysis, PC3 cells were seeded at a density of 0.8–1 million
cells per well in 6-well plates and incubated overnight with medium (DMEM: F12 (1:1)
containing 1% FBS, 100 U/mL penicillin and 100 μg/mL streptomycin). The next day,
the medium was removed, the cells washed and incubated for 1 h at 37 °C with fresh
medium. Afterwards, the plates were placed on ice for 30 min followed by incubation
with increasing concentrations of either 68/natGa-LF1 or 177/natLu-LF1 or 111/natIn-LF1
or 177/natLu-RM2 (1–100 nM) in phosphate-buffered saline binding buffer pH 7.4. After
the addition of the radioligands, the cells were incubated for 120 min at 4 °C. Non-
specific binding was determined in the presence of Tyr4-Bombesin at a final concentra-
tion of 1 μM. Then the cells were washed twice with ice-cold PBS, followed by
solubilization with 1 N NaOH and the cell-associated radioactivity was measured using
a gamma-counter. Specific binding was plotted against the total molar concentration of
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the added radiotracer. The Kd values and the concentration of the radiotracer required
to saturate the receptors (Bmax) were determined by nonlinear regression using Graph-
Pad (Prism 8 Graph Pad Software, San Diego, CA). For all the cell studies the values
are normalized for 1 × 106 cells per well and all data are from two independent experi-
ments with triplicates in each experiment.
Internalization studies
For internalization experiments, PC3 cells were seeded into 6-well plates and treated as
described above. Approximately 0.25 pmol of the respective radiopeptides were added
to the medium and the cells were incubated (in triplicates) for 0.5, 1, 2, 4 and 6 h at
37 °C, 5% CO2 for
177Lu- and 111In-labelled LF1 and for 15, 30, 60, 90, 120, 180 and
240 min at 37 °C, 5% CO2 for
68Ga-labelled LF1. To determine nonspecific membrane
binding and internalization, excess of Tyr4-Bombesin (final concentration 1 μΜ) was
added to selected wells. At each time point, the internalization was stopped by remov-
ing the medium and washing the cells twice with ice-cold PBS. To remove the
receptor-bound radioligand, an acid wash was carried out twice with a 0.1M glycine
buffer pH 2.8 for 5 min on ice. Finally, cells were solubilized with 1 N NaOH. The
radioactivity of the culture medium, the receptor-bound, and the internalized fractions
were measured in a γ-counter.
In vitro therapy studies with 177Lu-labelled LF1 in the presence or without rapamycin
For the in vitro therapy studies, PC3 cells were seeded at a density of 50,000–100,000 cells
(depending on the investigating time point: 100000, 75,000 and 50,000 cells for 24, 48, 72
h respectively) in 12-well plates and incubated overnight with cultivation medium at 37 °C
and 5% CO2. The next day, the medium was removed, the cells washed, and culture
medium containing either rapamycin (10 nM, dissolved in dimethyl sulfoxide (DMSO)) or
DMSO (control, the final concentration of DMSO in the culture medium was 0.5%) was
added. The plates were incubated at 37 °C and 5% CO2 for a period of 6 h. Afterwards, the
medium containing rapamycin or DMSO was removed and fresh medium was added in
each well. Furthermore, 1.85MBq of 177Lu-labelled LF1 was added to preselected wells.
The monotherapy (either with rapamycin or 177Lu-labelled LF1 alone) and combination
therapy study (177Lu-labelled LF1 in presence of rapamycin) were performed in parallel
with untreated cells which served as reference. The viability of the cells was accessed by
the trypan blue exclusion assay after incubation at 37 °C and 5% CO2 for 24, 48 and 72 h.
The experiment was performed twice in triplicate.
Statistical analysis
All data are expressed as the mean of values ± standard deviation (mean ± SD). Prism 8
Software (GraphPad Software) was used to determine statistical significance at the 95%
confidence level, with a P value of less than 0.05 being considered significant.
Results
Synthesis of the prochelator AAZTA5-(tBu)4
The synthesis route of AAZTA5-(tBu)4 is shown in Fig. 2. First, ring opening of 2-
nitrocyclohexanone was carried out in situ. A diazepane ring was formed by
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reaction with N,N′-dibenzyldiamine via a double nitro-Mannich reaction, 1. Hydro-
genolysis using Pd (OH)2 / C and H2 removed the benzyl protecting groups at the
endocyclic amines and simultaneously reduced the nitro group to an amine, 2. The
unstable product was directly reacted with tert-butyl bromoacetate without further
purification to form tetra alkylated compound, 3. Deprotection of the methyl ester
protecting groups were carried out by using 1 M lithium hydroxide solution and 1,
4-dioxane / H2O (ratio 2:1) to receive the bifunctional chelator AAZTA
5-(tBu)4, 4.
The analytic data of the intermediate products 1 and 3 as well as the prochelator 4
are presented below:
Product 1:
MS (ESI+): m/z (%): 440.3 (M +H+); calculated for C25H33N3O4: 439.25
1H-NMR (CDCl3, 400MHz, δ [ppm]): 7.29 (m, 10 H); 3.66 (s, 3 H); 3.67 (dd, J =
13.5 Hz, 4 H); 3.25 (dd, J = 14.0 Hz, 4 H); 2.63 (m, 4 H); 2.12 (m, 2 H); 1.59 (m, 2 H);
1.32 (m, 2 H); 0.78 (m, 2 H). 13C-NMR (CDCl3, 100MHz, δ [ppm]): 173.6 (s); 139.1
(s); 129.1 (s); 128.3 (s); 127.3 (s); 94.8 (s); 64.9 (s); 61.8 (s); 58.9 (s); 51.5 (s); 36.5 (s);
33.6 (s); 24.6 (s); 22.6 (s).
Product 3:
MS (ESI+): m/z (%): 686.5 (M +H+); 708.4 (M +Na+); calculated for C35H63N3O10:
685.45
1H-NMR (CDCl3, 400MHz, δ [ppm]): 3.65 (s, 4 H); 3.61 (s, 4 H); 3.22 (s, 3 H); 2.99 (d,
J = 14.1 Hz, 2 H); 2.85–2.65 (m, 4 H); 2.63 (d, J = 14.1 Hz, 2 H); 2.31 (t, J = 7.4 Hz, 2 H);
1.62–1.52 (m, 4 H); 1.44 (s, 18 H); 1.43 (s, 18 H); 1.25 (m, 2 H). 13C-NMR (CDCl3, 100
MHz, δ [ppm]): 174.4 (s); 172.9 (s); 170.9 (s); 80.9 (s); 80.4 (s); 65.3 (s); 63.2 (s); 62.6 (s);
59.4 (s); 52.1 (s); 51.6 (s); 37.3 (s); 34.3 (s); 28.3 (s); 28.3 (s); 25.9 (s); 21.8 (s).
Product 4 (AAZTA5-(tBu)4):
MS (ESI+): m/z (%): 672.4 (M +H+); 694.5 (M +Na+); calculated for C34H61N3O10:
671.44
1H-NMR (CDCl3, 400MHz, δ [ppm]): 3.60 (s, 4 H); 3.23 (s, 4 H); 3.00–2.97 (d, J =
14.1 Hz, 2 H); 2.88–2.60 (m, 6 H); 2.36–2.32 (t, J = 7.9 Hz, 2 H); 1.64–1.52 (m, 4 H);
1.43 (s, 18 H); 1.42 (s, 18 H); 1.24 (m, 2 H). 13C-NMR (CDCl3, 100MHz, δ [ppm]):
178.9 (s); 172.9 (s); 170.9 (s); 81.0 (s); 80.5 (s); 65.1 (s); 63.1 (s); 59.4 (s); 52.2 (s); 34.2
(s); 29.8 (s); 28.3 (s); 28.2 (s); 25.6 (s); 22.8 (s); 21.9.
Synthesis of the chelator-peptide conjugate
The synthesis yields of the peptide-chelator conjugate ranged from 30 to 40%. The pur-
ity and identity of the peptids was > 95% as determined by HPLC and mass spectros-
copy. The analytical data are depicted in Table 1.
A reception control (HPLC and mass spectroscopy) of the compound RM2 (GMP grade)
was also performed at our department and the analytical data are reported in Table 1.
Radiochemistry / quality control / stability
68Ga-labelled LF1
LF1 (3, 6 and 12 nmol) was labelled with gallium-68 in about 90% radiochemical purity
as determined by analytical HPLC, using a UV absorption at λ = 240 nm. The formation
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of one additional radioactive species (about 10%) was also observed. The retention time
of the main peak was 12.8 min while the retention time of the second radioactive spe-
cies was 12.1 min (Figure 1S). TLC excluded the creation of 68Ga-labelled colloids (Fig-
ure 1S). The maximum achieved apparent molar activity (Am) was approximately 60
GBq / μmol.
177Lu- and 111In-labelled LF1
LF1 was labelled with lutetium-177 and indium-111 at RT in 98% radiochemical purity
as determined by analytical HPLC, using a UV absorption at λ = 240 nm. Both analytical
methods, HLPC and TLC verified the presence of one radioactive species (the corre-
sponding radiolabelled peptide in each case) while the percentage of the free metal was
< 2%. The retention times of 177Lu- and 111In-labelled LF1 were 12.7 and 14.5 min re-
spectively (Figure 1S). The apparent molar activities (Am) were ranging between 10 and
20 GBq / μmol for 177Lu-labelled LF1 and approximately 10 GBq / μmol for the 111In-
labelled radioligand.
The stability of all the radiotracers over time was determined with RP-HPLC and nei-
ther radiolysis or decomposition was observed for a period of 4 h post labeling.
Lipophilicity / protein binding studies in human plasma
With a LogDoctanol/PBS of − 3.2 ± 0.04, − 2.9 ± 0.04 and− 2.8 ± 0.08 for the
68Ga-, 177Lu- and
111In-labelled LF1, respectively, all the radiotracers show a hydrophilic profile. (Lipophilicity =
the logarithm of the partition coefficient D, where D is the ratio of the distribution of a com-
pound in 2 solvents, here octanol and PBS).
To estimate the bioavailability of the three radiotracers in circulation, the extent of
human plasma protein binding was determined. Approximately 10% of the incubating
gallium-68, lutetium-177and indium-111 activity was found to be bound to plasma pro-
teins at the tested time points.
Saturation binding studies
Saturation binding studies were performed at 4 °C, in order to allow binding of the
radioconjugates to the receptor but to avoid endocytosis. All the radiotracers exhibited
affinity for the GRPr positive PC3 cells, with Kd values of 16.3 ± 2.4 nM for
68/natGa-
LF1, 10.2 ± 2.7 nM for 177/natLu-LF1 and 5.2 ± 1.9 nM for 111/natIn-LF1 (Fig. 3). The
Bmax values were also at the same level for the three radiotracers (0.4 ± 0.02 nM for
68/natGa-LF1, 0.8 ± 0.05 nM for 177/natLu-LF1 and 0.6 ± 0.06 nM for 111/natIn-LF1) which
correspond to approximately 4 × 105 receptors per cell.
The side-by-side comparison with the high affinity GRPr antagonist RM2 revealed
that the affinities of the new tested radiotracers were at the same range with 177/natLu-
RM2 (Kd: 5.4 ± 0.8 nM and Bmax: 0.8 ± 0.03 nM).
Table 1 Analytical data of LF1 and RM2
Compound Elemental composition Purity Calculated mass MS (ESI) Rt (min)
LF1 C80H116N18O22 > 95% 1682.89 m/z [M + H
+] 1623.89 m/z 13.8
RM2 C78H118N20O19 > 95% 1638.89 m/z [M
+·] 1638.89 m/z 12.8
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Internalization studies
68Ga-, 177Lu- and 111In-labelled LF1 were found to be well associated with the PC3 cells
within the incubation time frame (Fig. 4). Continued exposure of the cells to the radio-
active ligands resulted in a gradual increase of the total cell associated uptake from 15
min to 4 h for 68Ga-labelled LF1 and from 30min to 6 h for 177Lu- and 111In-labelled
LF1. 111In-labelled LF1 exhibited the higher total cell associated uptake (38.3 ± 2.5%)
(Figure 2S) followed by 177Lu-labelled LF1 (34.5 ± 2.3%) at 6 h (P = 0.0035) (Figure 2S).
68Ga-labelled LF1 revealed the lowest cell associated uptake (13.1 ± 0.24%) (Figure 2S).
At 6 h, the amount of specifically internalized activity was 9.2 ± 0.5% for 111In-labelled
LF1 and 8.9 ± 0.8% for 177Lu-labelled LF1 (P = 0.0054), while 68Ga-labelled LF1 exhib-
ited 2.8 ± 0.5% internalized activity at 4 h. Blocking experiments performed with excess
of Tyr4-BN, showed negligible nonspecific binding on the cell surface, while less than
0.3% of total added radioactivity was found to be internalized (data not shown) demon-
strating the high specificity of the GRPr-conjugates towards PC3 cells.
In vitro therapy studies with 177Lu-labelled LF1 in the presence or without rapamycin
An in vitro therapy study was performed aiming at evaluating the effect of combination
therapy on PC3 cells (Fig. 5). The viability of PC3 cells was verified 48 and 72 h after
treatment. The chosen dose of rapamycin for the in vitro therapy studies was 10 nM,
since it has been previously shown that rapamycin at this concentration has the greatest
cytostatic effect on PC3 cells (Dumont et al. 2013). The applied dose of 177Lu-labelled
LF1 was 1.85MBq. Combination therapy was found to be slightly more effective
Fig. 3 Saturation binding study on intact PC3 cells, using increasing concentrations of 68/natGa-LF1, 177/natLu-
LF1, 111/natLF-LF1 and 177/natLu-RM2, ranging from 1 to 100 nM. Dissociation constant (Kd) and maximum
number of binding sites (Bmax) were calculated from nonlinear regression analysis using GraphPad Prism
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compared to rapamycin or 177Lu-labelled LF1 alone (cell viability: approx. 40%, 48 and
72 h after the treatment). The treatment only with rapamycin showed a higher impact
compared to 177Lu-labelled LF1 on PC3 cells (cell viability: approx. 50% for rapamycin
and 70% 177Lu-labelled LF1 72 h).
Discussion
Prostate cancer, a complex and biologically heterogeneous disease, is the most common
type of cancer found in men, which often begins without symptoms. It is on a spectrum
varying from asymptomatic and slow-growing to a more aggressive and rapidly progres-
sive systemic malignancy (Kelloff et al. 2009). The survival rate could, therefore, be sig-
nificantly improved when early detection and personalized treatment take place.
Photon emission computed tomography (SPECT) and positron emission tomography
(PET) have gained a lot of attention in the management of prostate cancer due to their
high accuracy rate. The overexpression of peptide receptors on the surface of prostate
cancer cells played a pivotal role in this development and consequently generated inter-
est in the investigation of radiolabelled peptide-based probes for radio-theranostic ap-
plications. Prostate Specific Membrane Antigen (PSMA) and GRPr are the two
receptors, which are overexpressed on the surface of prostate cancer. Many efforts have
been made towards the development of PSMA- and GRPr-based imaging agents with a
particular focus on the low molecular weight PSMA inhibitors and the GRPr-based an-
tagonists. PSMA theranostics have proven great success in prostate cancer management
in the recent years (Eder et al. 2012; Afshar-Oromieh et al. 2017). However, due to low
PSMA expression not all patients suffering from prostate cancer can benefit from the
advantages of PSMA targeting. Therefore, there is an urgent need for these patients for
both characterization, planning, monitoring of the cancerous disease and treatment it-
self. Furthermore, because of the noticeable heterogeneity of prostate cancer at the time
of diagnosis (Schrecengost and Knudsen 2013), and even more during the recurrence
(Scher et al. 2013), it might be possible that the combination of imaging probes would
provide clinical advantages with respect to the imaging of various types and stages of
prostate cancer. GRPr and PSMA expression were compared on primary prostate can-
cer samples (Schollhammer et al. 2019; Touijer et al. 2019) as well as patients (Baratto
et al. 2020) providing evidence that the biodstribution for the two radioligands were
distinct. The so far preliminary data shows that the low metastatic risk PC patients
Fig. 4 Internalization rate and specific surface bound uptake after the incubation of PC3 cells with 68Ga-,
177Lu-, 111In-labelled LF1 within 4 or 6 h at 37 °C. Receptor-specific internalization and specific surface bound
activity expressed as percentage of the applied radioactivity. Nonspecific binding was determined in the
presence of 1 μM Tyr4-BN
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could benefit from GRPr targeting while in high-risk patients the PSMA-based radio-
tracers could serve as a valuable tool (Minamimoto et al. 2016).
Ongoing research efforts are currently directed to the development of both, PSMA-
and GRPr-based radiotracers with a particular focus of bridging radiopharmaceuticals
within a theranostic framework. The selection of an appropriate chelator, which bears
excellent coordination ability for diagnostic and therapeutic radionuclides, consists the
key step of this approach. The most frequently used chelator for radiopharmaceuticals
in clinical routine applications, DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraa-
cetic acid), has shown great ability for binding a variety of radiometals such as gallium-
68, indium-111, yttrium-90, cupper-64, lutetium-177. However, its applicability pre-
sents some limitations since efficient radiolabeling yields are achieved between 80 and
100 °C and the optimum labeling pH is 3 to 5 (Price and Orvig 2014). NOTA (1,4,7-
triazacyclononane-1,4,7-triacetic acid) and its derivative NODAGA (1,4,7-triazacyclono-
nane, 1-glutaric acid-4,7 acetic acid), enable sufficient labeling yields in lower tempera-
tures compared to DOTA but lower specific activities compared to the DOTA-
conjugates are reported. The biggest disadvantage of NOTA and NODAGA is that
their cavity is not suitable for the incorporation of therapeutic radionuclides such as
lutetium-177 (Eisenwiener et al. 2002). The acyclic chelating agent, HBED-CC (N,N
′-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid) which has
been used for the functionalization of PSMA-11, allows efficient radiolabelling with
gallium-68 even at ambient temperature, but it forms multiple radiolabelled species
(Eder et al. 2014). Therefore, a bifunctional chelator which could surmount the above
obstacles would be the optimum choice for the development of a new class of radio-
tracers. AAZTA5, a versatile chelator could be considered as a potential candidate for
this purpose. While AAZTA was initially developed for the chelation of Gd (III) as an
Fig. 5 In vitro therapy assessing the effect of monotherapy (rapamycin or 177Lu-labelled LF1) and combination
therapy (rapamycin and 177Lu-laballed LF1) on PC3 cells
Hofstetter et al. EJNMMI Radiopharmacy and Chemistry            (2020) 5:29 Page 14 of 19
MRI agent (Aime et al. 2004), it was shown that it exhibits high coordination capability
for a variety of metal ions such as gallium-68, indium-111, lutetium-177, scandium-44
(Eisenwiener et al. 2002; Waldron et al. 2013; Pfister et al. 2015; Tsionou et al. 2017;
Sinnes et al. 2019a). The mesocyclic structure of AAZTA5 facilitates efficient labeling
with high molar activities with a variety of radionuclides at RT and even at near neutral
pH, optimal conditions for small proteins. Throughout this study, our main goal was to
investigate whether and how N-terminal modulations, via the coupling with AAZTA5,
may influence the affinity of the derived GRPr-based radioligand towards GRPr. A par-
ticular focus on additional in vitro studies would allow us to assess the suitability of
these radiotracers for further evaluation. Attention was also given on the radiometal la-
belling properties of LF1 after its labeling with gallium-68 (PET), lutetium-177 (therapy,
SPECT) and indium-111 (SPECT, intraoperative applications).
Radiolabelling of LF1 with lutetium-177 and indium-111 supports its applicability
for sufficient labeling under mild conditions, even at nearly neutral pH. The high
stability in combination with the hydrophilic character may have resulted in the
low binding to the proteins of human serum (around 10%) as shown by our
in vitro studies.
When LF1 was labelled with gallium-68 two radiolabelled species were observed by
radio-HPLC while Waldron et al. reported the presence of three radioactive species
when AAZTA was labelled with gallium-68 under the same conditions (Waldron et al.
2013). Since the difference of the retention time between the two observed species was
less than 1 min we cannot fully exclude the formation of one additional species. Modifi-
cation at the iminodiacetate moiety of AAZTA where one of the acetate groups could
be replaced by a methyl group may prevent the formation of side products.
The observed differences of 68Ga- compared to 177Lu- and 111In-labelled LF1 with re-
gard to their radiochemical purity prompted us to further investigate if their GRPr
binding affinity is influenced and to what extent. Additionally, a side-by-side compari-
son of their binding affinities along with the binding affinity of 177/natLu-RM2, which
served as a reference peptide, was also performed. 111/natIn-LF1 (Kd: 5.16 ± 1.94 nM)
was the most affine exhibiting a Kd value similar to
177/natLu-RM2 (Kd: 5.42 ± 0.84 nM)
followed by 177/natLu-LF1 (Kd: 10.25 ± 2.73 nM).
68/natGa-LF1 (Kd: 16.27 ± 2.45 nM) was
still affine towards GRPr, however, the tracer with the lowest affinity almost by a factor
of 3 compared to 111/natIn-LF1. Since for AAZTA, the N2O4 coordination may also
occur in a competitive way with the favorable N3O3 coordination, this might be the
reason of the decreased affinity of 68/natGa-LF1. These findings were further supported
by the in vitro internalization studies, which demonstrated high and selective binding
of 68Ga-, 177Lu- and 111In-labelled LF1 to GRPr overexpressing cells. 177Lu- and 111In-
labelled LF1 exhibited a comparable profile in terms of total cell associated uptake and
percentage of specific internalized fraction while the corresponding values of 68Ga-la-
belled LF1 were considerably lower. The surface associated activity exceeded the
amount of internalized activity at all-time points for the three tested radiotracers. In
previous studies (Mansi et al. 2011), it was shown that RM2 at a concentration of
10 μM does not cause any effect on calcium mobilization after its incubation with PC3
cells, while an immunofluorescence assay revealed no receptor internalization of the
DOTA-Pip-conjugate RM2. The previously confirmed antagonistic potency of RM2 in
combination with our findings led us to the assumption that the introduction of
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AAZTA5 did not change the antagonist features of the statine-based motif and that
LF1 retains its GRPr-antagonistic profile.
These data may eliminate the applicability of 68Ga-labelled LF1 as a PET radiotracer.
However, AAZTA may be a suitable chelator for other PET radionuclides, such as
scandium-44 (Nagy et al. 2017) and cupper-64 (Greifenstein et al. 2020) and the poten-
tial of LF1 to serve as a PET tracer should be further evaluated. Furthermore,
scandium-44 and cupper-64 due to their longer half-life (3.97 and 12.7 h, respectively)
compared to gallium-68 (67.7 min) allow late imaging. This is of paramount importance
especially in case of GRPr expression imaging, since preclinical (Gourni et al. 2014) as
well as clinical data (Wieser et al. 2014) have shown that late imaging may be favorable
due to the efficient background clearance.
In a next step, the assessment of the potential of LF1 in serving as theranostic com-
pound for GRPr-positive tumors was investigated. An in vitro therapy study was exe-
cuted with the aim to evaluate the effect of combination therapy on PC3 cells (Edlind
and Hsieh 2014) after their treatment with rapamycin, a FDA approved specific inhibi-
tor of mTOR. Our preliminary in vitro data showed that combination therapy was
slightly more effective compared to monotherapy with 177Lu-labelled LF1. These
in vitro data is only an early evaluation of whether rapamycin before 177Lu-labelled LF1
treatment would have an additive effect; extensive in vivo studies needs to be per-
formed to safely suggest if the mTOR kinase inhibition may contribute to the
sensitization of the malignant prostate cancer cells to radiation.
In vivo studies are planned to be performed in order verify the preliminary in vitro
data and further define the ideal therapeutic doses and therapy regimens.
Conclusion
On the basis of the current results, LF1 labelled lutetium-177 and indium-111 appears
to have a considerable potential to serve as a versatile probe suitable for SPECT, ther-
apy and intraoperative applications. The ease of LF1 synthesis, the efficient radiolabel-
ing at RT with a variety of radiometals, the stable encapsulation of lutetium-177 and
indium-111 by AAZTA5 and their favorable in vitro performance renders them suitable
candidates for further extensive in vivo studies.
In vivo studies are planned to be performed which together with the already in vitro
data may provide a solid evidence for their clinical translation.
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